Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Vera Therapeutics, a US-based commercial-stage biotech company specializing in autoimmune kidney diseases, will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference in September 2026. The company's management aims to engage investors through fireside chats and one-on-one meetings, highlighting their…
Aclara Resources (ARAAF) is a development-stage rare earths company with a $701M market cap trading at $2.80. Neutral technicals, a shrinking float-relative liquidity profile, and a recent pickup in short interest create a tactical long trade: enter $2.70, stop $2.35, target $4.00 over a mid-term (45 trading days) horizon. The upside is driven by a…
Shattuck Labs (STTK) is a clinical-stage biotech developing SL-325, a DR3-blocking antibody that acts on the receptor side of the TL1A pathway. Phase 1 data released in June showed complete DR3 blockade at low doses and only 3.7% antidrug antibodies. The company recently raised $75M (06/10/2026) and trades at a market cap of roughly $701.5M. This t…
Descartes Systems Group announced it has acquired Extensiv, enhancing its warehouse management and omnichannel fulfillment solutions for third-party logistics providers (3PLs) and ecommerce brands. The acquisition strengthens Descartes' Global Logistics Network by integrating AI-powered capabilities to optimize inventory, order management, and fulf…
Kura Oncology, Inc., a biopharmaceutical company specializing in precision cancer medicines, announced that its management will present at three prominent healthcare investor conferences in September 2026. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. …
Unicycive Therapeutics, a clinical-stage biotech company focused on developing treatments for kidney diseases, announced its CEO will present at the upcoming H.C. Wainwright Global Investment Conference. The company is advancing novel therapies including oxylanthanum carbonate for hyperphosphatemia in dialysis patients and UNI-494 for acute kidney …
BitMine Immersion (BMNR) offers direct, corporate-level exposure to Ethereum through a large ETH treasury, a 2.7% staking yield and an operational platform that could outperform owning spot ETH for certain investors. The shares trade close to the company’s ETH holdings on a market-cap basis, while momentum and on-chain catalysts could re-rate the s…
Ocugen has dosed the first patient in its global Phase 3 registrational trial of OCU410, a one-time modifier gene therapy targeting multiple disease pathways for geographic atrophy secondary to dry age-related macular degeneration (dAMD). The therapy has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, enabling potential acce…
Invivyd, Inc. has appointed Marc W. Elia as CEO, who was previously Chairman and has driven the company's scientific and corporate strategy. The company is nearing the completion of Phase 3 studies (DECLARATION and LIBERTY) for its COVID-19 monoclonal antibody candidate VYD2311, with top-line data expected by end of Q3 2026. Invivyd is preparing re…
Tilray Brands' BrewDog division has launched 'Liquid Visions', a new premium craft beer series featuring four artist-designed cans and bold hop-forward flavors. This follows multiple awards BrewDog beers received at the 2026 World Beer Awards. The series will be rolled out across major UK grocery chains, including Tesco and Sainsbury's, aiming to r…
Ocular Therapeutix, a biopharmaceutical company focused on retinal disease treatments, announced its participation in several investor and scientific conferences in September and October 2026. The company will present updated data from its Phase 3 trials of AXPAXLI (OTX-TKI) for wet age-related macular degeneration and share information about its p…
Processa Pharmaceuticals announced participation in two upcoming investor conferences to discuss its lead BTK inhibitor drug candidate VT-7208 and recent acquisition of Vidya Therapeutics. The company completed a $200 million private placement to support development across immune-mediated diseases and plans special shareholder meetings for preferre…
RedHill Biopharma announced it has acquired exclusive global and U.S. commercialization rights to Ferring Pharmaceuticals' two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, in a transformative deal secured through proceeds from its prior Talicia divestiture. These drugs collectively generated about $37.5 million in U.S. net sales in 202…
Upstream Bio plans to initiate pivotal Phase 3 trials in Q1 2027 for verekitug, a novel TSLP receptor antagonist, in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The trials will evaluate a 400 mg dose administered every 12 weeks versus placebo, targeting broad patient populations. Successful Phase 3 results could lead to FDA…
Jade Biosciences, a clinical-stage biotech focused on autoimmune diseases, announced its participation in several upcoming investor conferences, including Wells Fargo, Citi, HC Wainwright, and Stifel events in September 2026. The company will host fireside chats and one-on-one meetings to discuss its pipeline, including lead product candidate JADE1…
Seres Therapeutics, a clinical-stage biotechnology company specializing in live biotherapeutics, announced its participation in the H.C. Wainwright Investment Conference and will provide an overview of its pipeline including SER-155 and SER-603. The company continues to develop treatments targeting oncology-related microbiome therapies and inflamma…
Harrow, Inc., a Nasdaq-listed North American ophthalmic disease management company, announced its management participation in three investor conferences in New York City during September 2026, featuring fireside chats and one-on-one investor meetings. The events aim to provide updates on company strategy and market presence.
Auddia Inc., a US-listed AI-first technology company, announced that its subsidiary Influence Healthcare has signed a Letter of Intent to sublease and eventually master lease a 24,000 sq ft specialty hospital in Texas with four operating rooms. This marks a significant milestone in Influence Healthcare's growth strategy and the company's broader pl…
Immunocore Holdings plc announced that its management team will participate in multiple investor conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare, and H.C. Wainwright Investment conferences. The sessions will include fireside chats and small group meetings, focusing on the …
Beam Therapeutics has appointed Eric Foster as Chief Commercial Officer to lead its commercial strategy and operations as the company progresses toward launching multiple precision genetic medicines, including the potential 2027 launch of risto-cel. Foster brings over 25 years of leadership experience in specialty and rare disease markets, enhancin…
Parabilis Medicines announced that its Chairman, President and CEO, Dr. Mathai Mammen, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The company focuses on developing novel alpha-helical peptides called Helicons targeting intracellular proteins previously considered undruggable, with lead drug c…
BioCryst Pharmaceuticals, a biotechnology company specializing in treatments for rare diseases including hereditary angioedema, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference. The presentation is scheduled for September 15, 2026, and will be webcast live. BioCryst currently markets ORLADEYO, its oral plasma…
Axogen, Inc., a leader in peripheral nerve repair technology, announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference, highlighting its commitment to innovative surgical solutions for nerve regeneration.
Rank One Computing Corporation (ROC), a U.S.-based Vision AI company, has finalized its acquisition of Zuccaro Technical Consulting LLC (ZTC). This acquisition integrates ZTC's digital forensics expertise and federal customer relationships into ROC's unified Vision AI platform, expanding ROC Evidence into a comprehensive investigative intelligence …
Tango Therapeutics, a clinical-stage biotech company focused on precision oncology therapies, will present at the 2026 Cantor Global Healthcare Conference. The company is advancing cancer treatments through synthetic lethality targets and will webcast its management discussion.
